PureTech Health plc (LON:PRTC – Get Free Report)’s stock price crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 130.41 and traded as low as GBX 127.60. PureTech Health shares last traded at GBX 131.20, with a volume of 4,566,746 shares trading hands.
PureTech Health Stock Performance
The company has a debt-to-equity ratio of 6.33, a current ratio of 6.59 and a quick ratio of 2.51. The firm has a fifty day moving average price of GBX 130.41 and a two-hundred day moving average price of GBX 126.96. The stock has a market capitalization of £319.36 million, a PE ratio of -2.85 and a beta of 0.81.
PureTech Health Company Profile
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.
Featured Stories
- Five stocks we like better than PureTech Health
- Costco’s Secret Growth Engine May Be Running Out of Gas
- Why Alphabet’s Pullback May Be an Opportunity in Disguise
- Capri’s Turnaround Is Taking Shape, But Is the Stock a Buy Yet?
- SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
